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INTRODUCTION
Since 2010, the WHO has recommended a single regimen as preferred first-line antiretroviral treatment (ART) for HIV that is well tolerated in pregnancy and can be taken with first-line tuberculosis (TB) treatment (ref) . Millions are now receiving the fixed-dose combination (FDC) of tenofovir disoproxil fumarate (TDF), lamivudine or interchangeable emtricitabine (FTC), often collectively referred to as XTC and efavirenz (EFV). The regimen has been very successful in treating tens of millions but has a low resistance barrier in the presence of even slightly compromised adherence, and significant side effects in a minority of people with HIV. The availability of new antiretrovirals at potentially similar or even lower prices than those in the current first-line regimen has led to consideration of the use of these agents in first-line treatment [1 & ,2,3 && ]. Tenofovir alafenamide (TAF; Gilead Health Sciences, California, USA) and particularly dolutegravir (DTG; ViiV Healthcare, London) are considered two potentially transformative antiretrovirals that address tolerability and toxicity as well as resistance for low-income and middle-income countries (LMICs). Recent WHO guidelines have recommended DTG as an alternative to EFV [4 & ,5 && ]. Both agents are covered in detail in other articles in this issue of Current Opinion.
HISTORY OF THE ADVANCE STUDY
ADVANCE was conceived after a WHO Think Tank on ART Optimization at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) by an informal group of clinicians, activists, academics, public health specialists and generic pharmaceutical company representatives from St.
Stephen's AIDS Trust, HIV i-Base, the Clinton Health Access Initiative (CHAI), Wits Reproductive Health and HIV Institute (Wits RHI) and Mylan, a generic pharmaceutical manufacturer. Previously, several expert ART optimization meetings -including the Second Conference on Antiretroviral Drug Optimization -had identified DTG/TAF/XTC as a potentially more durable, tolerable, safer and affordable regimen for LMICs than the current first-line. In the absence of sufficient evidence, such a recommendation had not moved beyond the discussion stage.
The group considered the ADVANCE trial -a randomized controlled trial (RCT) of potential new first-line regimens -to be necessary for two reasons. First, it was felt that WHO was unlikely to firmly recommend new regimens in the absence of robust evidence from an RCT, which would compromise confidence by governments to adopt the new regimens and generic manufacturers to scale up production. Second, and linked to the first, the originator companies of TAF (Gilead Sciences) and DTG (ViiV Healthcare) are commercial competitors, and although both have granted extensive licences to generic manufacturers in LMICs, they are unlikely to pursue an expensive regulatory study combining their drugs for markets that do not yield profits. Registration studies for new antiretrovirals for high-income countries typically do not include populations important in LMICs, such as pregnant women, children and adolescents, and those with TB and viral hepatitis.
The study was designed over the next 3 months, with details ironed out during the subsequent negotiations with donors and other stakeholders, and agreement that it could occur in a single site at Wits RHI in Johannesburg, South Africa. Existing large studies in Johannesburg run by the Wits RHI investigators, funded by the Bill and Melinda Gates Foundation and South African Medical Research Council, suggested that this site would suffice, especially as the study will recruit adolescents, and the site has access to this cohort.
In the second half of 2015, an opportunity for cofunding of the study arose separately with United States Agency for International Development (USAID) and Unitaid, with community mobilization and clinician education, a key aspect supporting the study. Both applications were successful, and funding began to flow during 2015 and 2016 for study design, regulatory submissions and engagement with other stakeholders, including the originator companies, both of whom agreed to donate study drug. Formal engagement with the South African government gained high-level support for the study, especially when potential cost savings were noted [6] . This engagement, along with CHAI, has catalysed a series of discussions with senior government officials as well as generic manufacturers, preparing the country for the next antiretroviral tender, which, by virtue of the size of South Africa's epidemic, accounts for almost a third of all global generic antiretroviral consumption. USAID asked that the National Institutes of Health International Data Safety Monitoring Board (DSMB) for HIV studies be used as the formal DSMB, which suggested several modifications to the protocol.
During this time, the original informal group was formalized as the OPTIMIZE Consortium, and included WHO, CHAI and various academic groups, as well as the pan-African community group AfroCAB, with a broader mandate around improving antiretroviral regimens. Collaborations were extended to other researchers working on similar projects, including within the National Institutes for Health and AIDS Clinical Trials Group led projects, and the protocol circulated freely.
The ADVANCE protocol was finalized during 2016, largely by email but using one formal scientific advisory group meeting at the 2016 CROI, and successfully submitted to the various regulators within South Africa. The last study drug was received at the site in December 2016, and the first 45 patients enrolled in the study in February 2017, with active support for recruitment from South Africa's Treatment Action Campaign. Enrolment is projected to be completed by the end of 2017, with KEY POINTS ADVANCE will make regulatory-level evidence available for two new regimens, using tenofovir alafenamide and dolutegravir, for normative guidance advice.
The study was conceived and designed by a broad array of stakeholders, including activists and manufacturers, with open and consultative discussion on protocol design.
The new regimens offer tolerance, resistance barrier and cost benefits over the currently used first-line antiretroviral regimen.
Results should be available for 48-week data by the first quarter of 2019.
Towards a universal antiretroviral regimen 48-week results available during the first quarter of 2019.
CRITICAL DEBATES SURROUNDING THE STUDY DESIGN
The critical inclusion and exclusion criteria are detailed in Table 1 . TAF was selected for study as the likely nucleotide reverse transcriptase inhibitor to succeed TDF, and its low dose suggested significant cost savings over TDF in a generic market; preliminary data also suggested less renal and bone-density impact. DTG, with proven tolerability benefits over EFV and a far greater resistance barrier, was selected as a cost neutral or even cheaper option. No other integrase inhibitor was available at the time that combined cost benefit and potential for daily FDC development, with studies planned to look at what happens to those who develop TB or pregnancy while on study. It was felt that it was important to keep the study as close to 'real world' as possible, so exclusion criteria were kept to a minimum. TB and pregnancy are being specifically studied in separate research projects, so excluding these patients at baseline was felt to be acceptable, but patients who fall pregnant or get TB will be retained.
A noninferiority design was selected, and initially compared TAF with TDF in the presence of XTC (ADVANCE will use FTC) and DTG, as DTG had clear benefits over EFV, as a two-arm study. However, several commentators and donors felt that the level of evidence for starting millions of people on a new regimen needed to be robust, and that this justified including a third arm, the standard of care arm being TDF/FTC/EFV (Fig. 1) . The TDF/FTC/DTG arm was retained, in case issues with TAF arose, and allowing development of DTG-containing regimens to continue. This added to cost and complexity, but after consulting with stakeholders, community advisors and the DSMB, was felt to be sufficiently compelling to accommodate.
The study uses traditional 48-week and 96-week virological suppression endpoints and toxicity monitoring seen in similar registration trials, including renal and bone endpoints. Pharmacokinetic substudies have been nested within the main study, along with quality of life, sleep and psychiatric symptom questionnaires, to carefully map the side effects seen within the various regimens.
At the end of 2015, Gilead brought the ADVANCE group's attention to new data surrounding a major potential drug interaction with TAF and rifampicin. The study was adapted to accommodate this, with patients who develop TB being moved from TAF to TDF, and for DTG, doubling the dose and giving the drug twice daily.
In 2016, the DSMB requested that adolescents, a group thought to be important to include in the protocol, be analysed separately, and the adult portion of the protocol powered separately. This also added to cost and complexity, and increased the size of the study, but again was felt to be compelling enough to accommodate.
CONCLUSION
Traditionally, drug and regimen development have been largely led by the pharmaceutical industry or independent researchers. ADVANCE represents a unique consortium of stakeholders, including policy makers, nongovernmental agencies, activists, generic manufacturers and originators, that has 
